Is multiple myeloma survival affected by blood type? HealthTree for Multiple Myeloma studied this question by drawing conclusions from the self-reported HealthTree Cure Hub database which included 1,173 individuals. The selected patients had validated profiles of their medical records including labs, genetics and prior lines of therapy. Patients not reporting a blood type were excluded from the study.
- 458 patients reported having A blood type
- 56 patients reported having AB blood type
- 155 patients reported having B blood type
- 504 patients reported having O blood type
- The researchers analyzed the relationship between survival time (total time to next treatment) and a myeloma patients' ABO blood type. Additional analysis was performed to determine if blood type was linked to risk status.
- The results showed statistical significance (p-value = 0.040) that there was a relationship between total time to next treatment and blood type, with O blood type having the longest average time to next treatment by 250 days.
Blood Type Average days to next treatment O blood type 2027 days A blood type 1762 days AB blood type 1882 days B blood type 1747 days
There was not statistical significance in average survival time (p-value = 0.138).
We also investigated whether or not patients in certain ABO blood groups are more inclined to have high-risk mutations. We categorized patients as high risk and standard risk-based on guidelines defined by Mayo Clinic’s mSMART guidelines. We found that there was no statistical significance (p-value = 0.797) and concluded that patients are equally likely to be considered high risk for all ABO blood groups.
Further work should be performed to identify why O blood type is related to longer remission times.
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd).